Replies to post #1106 on Can Fite BioPharma Ltd (CANF)

[Chemist823]

That's the question, whether there will be more dilution or will a big partnership deal come along. Nash is a huge market and there have been some big deals recently. Either the street is not convinced by the data, which looks really great for NASH as well as liver cancer, or the deal is coming. The market cap is only 32 million so I think this is worth a shot, bought 4000 shares and will be watching. When you look at a couple year chart looks like this is poised to have a big move.

[Oren1976]

If u look for solid science Israeli biotech vblt . Canf is low market cap yes but far from being a company with a working drug. My take in the company none of their drug works. And even if ra or psoriasis work it's problematic work because psoriasis it affect after 3 years or 2 years